Abrégé

The present invention relates to a composition comprising a probiotic composition comprising a Lactobacillus salivarius strain and a Lactobacillus gasseri strain. The invention further relates to the nutraceutical and therapeutical uses of such compositions in oxytocin-related neuropsychiatric disorders, in particular autism or anxiety related disorders selected from depression and eating disorders.

Classes IPC  ?

• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61K 35/745 - Bifidobactéries
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61P 25/22 - Anxiolytiques
• A61P 25/24 - Antidépresseurs

Abrégé

The present invention concerns new tricyclic spirolactams (TriSLas) compounds and their use as a drug, in particular for the prevention and/or treatment of a mycobacterial infection or for the treatment of a disease caused by infection with a Mycobacterium. The tuberculosis drug development pipeline requires further supplementation with additional candidates, ideally acting on novel targets (to minimize cross-resistance) and impacting on drug-tolerant bacilli to shorten treatment. The inventors of the present invention have identified new tricyclic spirolactams (TriSLas) compounds with particular activity against M. tuberculosis.

Classes IPC  ?

• C07D 498/20 - Systèmes condensés en spiro
• A61K 31/438 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle étant condensé en spiro avec des systèmes carbocycliques ou hétérocycliques
• A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
• A61K 31/4545 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pipampérone, anabasine
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/4747 - QuinoléinesIsoquinoléines condensées en spiro
• A61K 31/537 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en spiro ou formant une partie de systèmes cycliques pontés
• A61K 31/5386 - 1,4-Oxazines, p. ex. morpholine condensées en spiro ou formant une partie de systèmes cycliques pontés
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
• C07D 498/10 - Systèmes condensés en spiro

Abrégé

The present invention relates to the field of the measuring of temperature of an area inside an object. The gold standard to measure temperature changes during thermal therapies is magnetic resonance imaging but ultrasound scanners seem to be a good alternative because they are portable devices. Several methods have been developed to estimate temperature with ultrasound, by measuring thermal strain, or acoustic attenuation coefficient, or backscatter energy but methods used actually need to be optimized. That's why the inventors worked on a more sensitive method. Thus, the present invention relates to a method for measuring of temperature of an area inside an object implying several ultrasound echoes obtained at different times.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• G01K 11/22 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant la mesure d'effets acoustiques
• G01K 11/24 - Mesure de la température basée sur les variations physiques ou chimiques, n'entrant pas dans les groupes , , ou utilisant la mesure d'effets acoustiques de la vitesse du son

Abrégé

The present application relates to a method of treating a respiratory viral infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an agent that depletes plasmacytoid dendritic cells. Another object of the present application relates to a kit of part comprising said agent and at least one further therapeutic agent as a combined preparation for simultaneous, separate or sequential use in the treatment of a respiratory viral infection in a subject in need thereof.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques

Abrégé

The present invention relates to the field of the treatment of cancer. In this study, the inventors found that VDAC2 is heterogeneously expressed in MM cells. VDAC2 protein expression correlated with BAK but not with BAX protein levels. Transient silencing of VDAC2, but not VDAC1 or VDAC3, sensitized MM cells to intrinsic mitochondrial apoptosis signals, alongside with the induction of pre-activated BAK and the increase of global, MCL1 and BCL2 mitochondrial priming. They also found a that a VDAC2 compound, efesevin recapitulated the sensitization effect of VDAC2 knock-down on BH3 mimetics apoptotic response. This novel VDAC2 modulator sensitized MM cells to BH3 mimetics targeting MCL1 (S63845) or BCL2 (Venetoclax) without modifying BAK or BAX protein expression. The efficiency of the VDAC2 modulator was directly correlated with the levels of VDAC2 protein. To better understand the VDAC2/BAK interplay, The inventors generated VDAC2 KO myeloma cells. VDAC2 KO cells exhibited an important decrease of BAK protein expression while BAX remained unchanged. Accordingly, VDAC2 KO cells completely lost their mitochondrial priming. Interestingly, they also found that BAK KO myeloma cells displayed decreased levels of VDAC2. The reciprocal regulation between VDAC2 and BAK was dependent on both the proteasome and lysosome degradation pathways. Thus, the present invention relates to a combination of a VDAC2 modulator and a BH3- mimetics compound for use in the treatment of a cancer in a subject in need thereof.

Classes IPC  ?

• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention concerns the treatment of Fibrotic interstitial lung diseases (Fibrotic ILDs) and particularly Progressive pulmonary fibrosis (PPF) such as idiopathic lung fibrosis (IPF). In particular inventors develop antisense oligonucleotides targeting HSPB5 and study their effects on the development of experimental pulmonary fibrosis. Specific antisense oligonucleotides (ASO) were designed and screened in vitro, based on their ability to inhibit both human and murine HSPB5 expression. One of them, ASO22, was selected by its capacity to inhibit TGF-β1-induced expression of HSPB5 and additional key markers of fibrosis such as PAI-1, collagen, fibronectin and α-SMA in fibroblastic human CCD-19Lu cells as well as PAI- 1 and α-SMA in pulmonary epithelial A549 cells. Intra-tracheal or intravenous administration of ASO22 in bleomycin-induced pulmonary fibrotic mice decreased HSPB5 expression and reduced fibrosis as measured by the decrease in pulmonary remodeling, collagen accumulation and Acta2 and Col1a1 expression. Altogether, these results suggest a real interest of using an antisense oligonucleotide strategy targeting HSPB5 for the treatment of pulmonary fibrosis.

Classes IPC  ?

• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides

Abrégé

The invention relates to a device for trapping at least one cell pair in a solution containing at least one first cell (C1) of a first type and at least one second cell (C2) of a second type, comprising: —a microfluidic channel (3) adapted for a unidirectional flow (F) of the solution; —a first trap (1) comprising a pair of first fingers (10a, 10b) arranged in the microfluidic channel (3), at least one of said first fingers (10a, 10b) being coupled to a respective first actuator (11a, 11b), said first actuator being configured to adjust the first trap (1) along a direction transversal to the flow (F) between an open position allowing passage of the first cell between the first fingers (10a, 10b) and a closed position adapted to a size of the first cell to allow trapping the first cell between the first fingers (10a, 10b); 15—a second trap (2) comprising a pair of second fingers (20a, 20b) arranged in the microfluidic channel (3), at least one of said second fingers (20a, 20b) being coupled to a respective second actuator (21a, 21b), said second actuator being configured to adjust the second trap (2) along a direction transversal to the flow (F) between an open position allowing passage of the second cell between the second fingers (20a, 20b) and a closed position adapted to a size of the second cell to allow trapping the second cell between the second fingers (20a, 20b); wherein the first trap (1) is arranged relative to the second trap (2) so as to form, when the first and second traps are in the closed position, a cell pair comprising the trapped first and second cells such that the second cell is in physical or chemical interaction with the first cell.

Classes IPC  ?

• B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes

Abrégé

A process for isolating or extracting rare cells from a biological sample including filtering a biological sample, which may be treated or diluted, through a filter that has a pore size, pore density or other physical properties that retain rare cells, but which permits other kinds of cells to pass through the filter.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/554 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques le support étant une cellule ou un fragment de cellule biologique, p. ex. cellules de bactéries, de levure

Abrégé

The invention relates to the first hydrolase that specifically digests the archaeal type of a peptidoglycan (PG), the major component of the cell wall of methanogens, named Talosaminidase. The enzyme consists of a signal peptide, several bacterial IG domains, a glycosyl hydrolase, several archaeal PG binding domains and a peptidase domain. The double enzymatic activity for the glycosyl hydrolase and the peptidase maximizes the lysis of archaeal cells with a cell wall of the archaeal PG-type. Engineering the enzyme by removing the signal peptide and bacterial IG domains and keeping only the archaeal PG binding, glycosyl hydrolase and peptidase made the enzyme easier to express and purify, without negatively influencing the enzymatic activity. Therefore, engineered Talosaminidase can be used to regulate populations of archaeal methanogens in the industrial, agricultural and medical settings, and consequently methane production.

Classes IPC  ?

• C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p. ex. cellulases, lactases
• A61P 31/04 - Agents antibactériens
• C12N 9/50 - Protéinases
• C12N 9/52 - Protéinases provenant de bactéries

Abrégé

The present invention relates to a compound of formula (I) for its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61K 40/13 - Lymphocytes B
• C07D 235/18 - BenzimidazolesBenzimidazoles hydrogénés avec des radicaux aryle liés directement en position 2
• C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 471/04 - Systèmes condensés en ortho
• C07K 14/54 - Interleukines [IL]
• C12N 5/0781 - Cellules BLeurs progéniteurs

Abrégé

Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer's disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP/PS1 mouse model of Alzheimer's disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer's disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The invention concerns a compound of formula (I) wherein R, R1and R2are independently selected form the group consisting of: a hydrogen atom, a halogen atom, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carboxyl group, an amido group comprising from 1 to 10 carbon atoms, and an imino group, possibly substituted by an alkyl group, linear, cyclic or branched, saturated or unsaturated, and wherein R3, R4, R5and R6 are independently selected form the group consisting of: a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, linear, cyclic or branched, saturated or unsaturated, possibly substituted, comprising from 1 to 10 carbon atoms, an alkoxy group comprising from 1 to 10 carbon atoms, an acyl group comprising from 1 to 10 carbon atoms, a carbonate group from 1 to 10 carbon atoms, a carboxyl group, and a cyano group, for use as neuroprotectants, or in the treatment of disorders with reduced NAD metabolism.

Classes IPC  ?

• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p. ex. carbazole
• A61P 3/04 - AnorexigènesMédicaments de l'obésité
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

Control tissues and different lesions of either adenomyosis or endometriosis were exposed in vitro during 24 hours either to vehicle (DMSO) or different doses of BYL719 or ST420, a PIK3CA inhibitor. Inventors observed that lesions treated with DMSO had a higher recruitment of the PIK3CA pathway compared to healthy endometrium. Importantly, both inhibitors were able to shut down the phosphorylation of AKT. They concluded that PIK3CA inhibition is a good therapeutic target for patients with endometriosis and adenomyosis. They also investigated the role of the PIK3CA pathway in myoma, another benign uterine condition. They observed that either alpelisib or ST420 were able to inhibit the pathway in myoma. They concluded that myoma demonstrate PIK3CA/AKT pathway activation with somatic mutation and are accessible to targeted treatment. Accordingly, the invention relates to method for treating uterine disease in a subject in need thereof comprising a step of administrating the subject with a therapeutically effective amount of PIK3CA inhibitor such as compound of formula (I), or a deuterated or tritiated form of the compound of formula (I), BYL719.

Classes IPC  ?

• A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
• A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to the use of a Lesion Progression Probability Score (LPPS) for predicting the risk of progression of a tumor lesion in a subject suffering from lung cancer when treated by immunotherapy, wherein the tumor lesion comprises a core tumoral region and a peritumoral region referred to as a ring and the LPPS of each lesion comprises 6 specific radiomics features. The invention also relates to the use of a patient progression probability score (PPPS) for predicting the risk of disease progression in a subject suffering from lung cancer when treated by immunotherapy, wherein the PPPS combines the LPPS values of all analyzed tumor lesions of the subject with a volume equal to or higher than a minimum volume Vmin. The invention also relates to therapeutic uses of immunotherapy in subjects with lung cancer with a low or moderate predicted risk of disease progression using the PPPS.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• G06N 3/02 - Réseaux neuronaux
• G06T 7/00 - Analyse d'image
• G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

Abrégé

Translating bacterial-based therapies to clinical success has yet been proven challenging, facing targeting inconsistencies, formulation issues and immune system noncompliance that can lead up to sepsis. To counter these limitations, the invention provides the Smart Polymer Shield (SPS) for the encapsulation of individual live cells.

Classes IPC  ?

• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 9/107 - Émulsions
• A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
• A61P 35/00 - Agents anticancéreux

Abrégé

The inventors have now succeeded in developing arylsulfonium salts, in particular triarylsulfonium salts and dibenzothiophenium salts and a new use of said arylsulfonium salts. These compounds have the advantage of having a thioaryl group as leaving group, which allows all side products to be separated from the radiolabelled product. Said compounds are therefore useful tools in a method for synthesizing iodo- or astatoarryl compounds, in particular radioiodo- or radioastatoaryl compounds. The present invention relates to a method for synthesizing iodo- or astatoaryl compounds comprising the reaction of an arylsulfonium compound with an iodide or astatide salt, respectively. The invention also relates to arylsulfonium compounds as such. The invention also concerns a method of synthesizing an iodo- or astatolabelled biomolecule and/or vector using said iodo- or astatoraryl compound.

Classes IPC  ?

• A61K 51/04 - Composés organiques
• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07C 17/093 - Préparation d'hydrocarbures halogénés par remplacement par des halogènes
• C07C 45/63 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par introduction d'atomes d'halogènePréparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par des réactions ne créant pas de groupe C=O par substitution d'atomes d'halogène par des atomes d'autres halogènes
• C07C 201/12 - Préparation de composés nitrés par des réactions ne créant pas de groupes nitro
• C07C 247/06 - Composés contenant des groupes azido avec des groupes azido liés à des atomes de carbone acycliques d'un squelette carboné étant saturé et contenant des cycles
• C07C 253/30 - Préparation de nitriles d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes cyano
• C07C 381/12 - Composés sulfonium
• C07D 213/61 - Atomes d'halogènes ou radicaux nitro
• C07D 333/76 - Dibenzothiophènes
• C07D 409/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique

Abrégé

The present invention is in the field of cancer treatment. It relates to the use of a liver metastasis-specific radiomics-based signature for predicting in a subject suffering from a metastatic cancer with liver metastasis: (a) survival if treated by immunotherapy without preliminary liver focal radiotherapy, (b) response to immunotherapy without preliminary liver focal radiotherapy, (c) survival if treated by liver focal radiotherapy followed by immunotherapy, (d) response to liver focal radiotherapy followed by immunotherapy, or (e) any combination of (a) to (d). It further relates to a method for predicting any one of (a) to (e) based on the same liver metastasis-specific radiomics-based signature, as well as specific therapeutic uses of immunotherapy, with or without previous liver focal radiotherapy, in metastatic cancer subjects with liver metastasis, the selection of the specific treatment being made depending on the same liver metastasis-specific radiomics-based signature.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
• G06F 18/00 - Reconnaissance de formes
• G06T 7/00 - Analyse d'image
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
• A61B 6/03 - Tomographie informatisée
• A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations

Abrégé

The present invention relates to compositions, and in particular to pharmaceutical compositions, comprising, or even consisting of, a suspension of bacteriophages of the class Caudoviricetes, the bacteriophages having lytic activity against at least one Gram-positive bacterial strain, at a titer of at least 108 PFU/mL, in a dispersing medium comprising, or even consisting of: - at least one non-ionic surfactant, and in particular a single non-ionic surfactant, selected from the polysorbate family, at a molar concentration greater than its critical micelle concentration, but not exceeding 2 mg/mL, and/or the poloxamer family, at a concentration ranging from 0.005% (w/v) to 30% (w/v); - one or more neutral salts formed from a pair of monovalent ions, the total molar concentration of which is in the range from 75 to 160 mM; - a buffer mixture imparting to the composition a pH from 6.0 to 7.9, and preferentially from 7.0 to 7.5, typically selected from hydrogen phosphate ion/dihydrogen phosphate, citric acid/citrate ion and citric acid/hydrogen phosphate ion ion pairs, wherein the molarity of the buffer mixture is in the range from 4 mM to 100 mM; - water, wherein the composition comprises less than 0.9 bacterial endotoxin units per mL and a total protein concentration of less than 0.09 mg/mL, and wherein the bacteriophage suspension in the dispersing medium has an osmolality of between 150 mOsm/kg and 600 mOsm/kg; the invention also relates to associated methods and uses.

Classes IPC  ?

• A61K 35/76 - VirusParticules sous-viralesBactériophages
• A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
• A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
• A61M 3/00 - Seringues médicales, p. ex. clystèresIrrigateurs
• A61P 31/04 - Agents antibactériens
• C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification

Abrégé

HDACs are undoubtedly the most extensively studied epigenetic enzymes, and numerous inhibitors have been developed. However, the results of clinical trials with HDAC inhibitors in various cancers remain rather mitigated. To better understand the role of HDACs in melanoma, the inventors analysed the correlation between HDAC expression and patient survival in the TCGA cohort. In particular, the present invention relates to a method for treating melanoma in a subject in need thereof comprising administrating to the subject a therapeutically effective amount of an inhibitor of HDAC4.

Classes IPC  ?

• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/4704 - 2-Quinolones, p. ex. carbostyrile
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

T-cell acute lymphoblastic leukemias (T-ALL) are aggressive hematological malignancies associated with poor clinical outcome. TP53 alterations (TP53Alt) were rarely identified in T-ALL at diagnosis and their prognostic impact remains unclear. In a cohort of 476 adults and pediatric T-ALL, TP53Alt were observed in 4% of cases and were associated with chemoresistance and poor prognosis. APR-246, a small compound which restores wild-type configuration to mutated p53, showed efficacy in T-ALL harboring TP53 mutations. More importantly, in TP53 germline T-ALL, Notch 1 pathway gain of function mutations were associated with substantial sensitivity to APR-246. Mechanistically, Notch 1 activation via p53 downregulation and subsequent ferroptosis induction led to preferential APR-246 sensitivity. Given that Notch 1 pathway oncogenic activation is present in more than 70% of T-ALLs, these observations pave the way for promising perspectives in T-ALL treatment which could benefit from the Achilles heel associated with Notch 1 activation sensitizing leukemia cells to APR-246-induced ferroptosis, thus extending the use of APR-246 in T-ALL beyond TP53 alterations.

Classes IPC  ?

• A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p. ex. quinuclidine
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to chemically modified adeno-associated (AAV) viruses and their use in gene therapy.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C12N 15/86 - Vecteurs viraux

Abrégé

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

Classes IPC  ?

• A61K 31/197 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p. ex. acide gamma-aminobutyrique [GABA], bêta-alanine, acide epsilon-aminocaproïque ou acide pantothénique
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Hypomelanosis of Ito is a clinical term for patients with mosaic syndromes characterized by skin hypopigmentation and developmental disorders. The genetic causes of these rare diseases remain largely unclear. Here, we report that GNA13 is a new gene that causes Hypomelanosis of Ito. We identified an identical mutation in this gene in four unrelated patients exhibiting pigmentary mosaicism. In depth functional investigations revealed that this is an activatory mutation that alters the cytoskeleton and morphology of melanocytes via a hyperactivation of the RHOA/ROCK signalling pathway. Our results also indicate that this pathology does not necessarily originate from a decreased production of melanin, but can originate from a defect in melanosome transfer to keratinocytes due to cell shape alterations. Thus, our findings suggest for the first time a mechanism by which the clinical symptoms of patients with Hypomelanosis of Ito appear, and pave the path for new therapeutic approaches. Altogether, the present invention relates to a method for treating a patient suffering from hypomelanosis of Ito by administering a ROCK inhibitor and/or RHOA inhibitor.

Classes IPC  ?

• A61K 31/015 - Hydrocarbures carbocycliques
• A61K 31/38 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle
• A61K 31/415 - 1,2-Diazoles
• A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
• A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
• A61K 31/517 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinazoline, périmidine
• A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques

Abrégé

Hepcidin is an hyposideremic hormone made primarily by the liver. To address the role of hepcidin made specifically by the intestine in lowering serum iron, the inventors generated transgenic mice overexpressing the peptide specifically in this tissue. These mice exhibit, at one month of age, a severe hyposideremia, along with decreased haematological indices and hair loss. Mechanistically, they showed that intestinal hepcidin made by the transgenic mice had no effect on intestinal ferroportin, but, in contrast, induced a striking down-regulation of Divalent Metal Transporter 1 (DMT1) protein at the apical side of the enterocyte. Intestinal hepcidin can be produced in the apical side suggesting the direct role of apical hepcidin on DMT1. To confirm the therapeutic capacity of hepcidin on regulation of DMT1, the inventors developed probiotics (engineered recombinant lactic acid bacteria), capable of delivering hepcidin directly into the lumen of the intestine. They orally administrated daily these probiotics in hemochromatosis mice model, after 28 days of treatments they observe a decrease of iron overload. Thus, the present invention relates to a method for preventing or treating an iron overload associated disease in a subject in need thereof, comprising administering locally in the gut of the subject hepcidin.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61K 35/747 - Lactobacilles, p. ex. L. acidophilus ou L. brevis
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

in vivoin vivo, showing that Tgfbi can indeed regulate cachexia-associated cytokine production via macrophage integrin signaling. Thus, the present invention relates to an anti-TGFBI antibody and uses thereof.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61P 35/00 - Agents anticancéreux
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

The present disclosure relates to a method of treating a cholangiocarcinoma in a human subject in need thereof, comprising administering a therapeutically effective amount of an anti-Claudin-1 antibody to the human subject.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 33/243 - PlatineSes composés
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases

Abrégé

Aortic valve stenosis (AS), is the most frequent valvular heart disease in Europe and affects more than 1 in 4 people over 65 years old. AS progression from fibrotic thickening to valvular leaflets calcification leads to heart failure development and eventually to death within 2 to 5 years after symptoms occurrence. The inventors now show that endothelin receptor type B (ETB) activation with an agonist decreased the calcium content of VIC. Therefore, the present invention relates to the use of endothelin receptor type B (ETB) agonists for the treatment of aortic valve stenosis.

Classes IPC  ?

• A61K 38/22 - Hormones
• A61F 2/24 - Valvules de cœur

Abrégé

The present invention relates to serotonin derivatives of general formula (I), and their use in the pharmaceutical field, in particular for preventing or treating metalloptosis associated disorders. The invention also relates to new serotonin derivatives of general formula (I) and their use for preventing or treating iron- and/or copper-associated disorders.

Classes IPC  ?

• A61K 31/4045 - Indole-alkylaminesLeurs amides, p. ex. sérotonine, mélatonine
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• C07D 209/16 - Tryptamines
• C07D 209/30 - IndolesIndoles hydrogénés avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone de l'hétérocycle
• C07D 401/06 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
• C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles

Abrégé

The present invention concerns monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein and therapeutic compositions comprising thereof, and in particular their use in the treatment of a mammal suffering from a solid cancer, preferably chosen from cancers resistant to radiation therapy and cancers sensitive to radiation therapy.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to a method for generating T cell progenitors from pluripotent stem cells, and to the therapeutic use of the generated T cell progenitors.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 5/0789 - Cellules souchesCellules progénitrices multipotentes

Abrégé

ortho44 solution or human and rat microsomes. The present invention relates to astatoaryl compounds, a method for synthesizing astatoaryl compounds comprising the reaction of an aryl compound carrying a leaving group with astatine. The invention also concerns a method of synthesizing an astatolabelled biomolecule and/or vector using said astatoraryl compound.

Classes IPC  ?

• C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
• C07F 13/00 - Composés contenant des éléments des groupes 7 ou 17 du tableau périodique
• A61P 35/00 - Agents anticancéreux
• C07C 29/147 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction d'un groupe fonctionnel contenant de l'oxygène de groupes contenant C=O, p. ex. —COOH d'acides carboxyliques ou de leurs dérivés
• C07C 29/62 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par introduction d'atomes d'halogènePréparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par substitution d'atomes d'halogène par des atomes d'autres halogènes
• C07C 33/46 - Alcools non saturés halogénés ne contenant que des cycles aromatiques à six chaînons dans la partie cyclique
• C07C 41/30 - Préparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther par augmentation du nombre d'atomes de carbone, p. ex. par oligomérisation
• C07C 43/23 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle aromatique à six chaînons contenant des groupes hydroxyle ou O-métal
• C07C 51/16 - Préparation d'acides carboxyliques, de leurs sels, halogénures ou anhydrides par oxydation
• C07C 67/08 - Préparation d'esters d'acides carboxyliques par réaction d'acides carboxyliques ou d'anhydrides symétriques avec le groupe hydroxyle ou O-métal de composés organiques
• C07C 231/02 - Préparation d'amides d'acides carboxyliques à partir d'acides carboxyliques ou à partir de leurs esters, anhydrides ou halogénures par réaction avec de l'ammoniac ou des amines
• C07C 231/12 - Préparation d'amides d'acides carboxyliques par des réactions n'impliquant pas la formation de groupes carboxamide
• C07C 309/30 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné de cycles aromatiques à six chaînons non condensés de cycles aromatiques à six chaînons substitués par des groupes alkyle
• C07C 63/70 - Acides monocarboxyliques
• C07C 63/68 - Composés comportant des groupes carboxyle liés aux atomes de carbone de cycles aromatiques à six chaînons contenant des atomes d'halogène
• C07C 69/76 - Esters d'acides carboxyliques dont un groupe carboxyle estérifié est lié à un atome de carbone d'un cycle aromatique à six chaînons
• C07C 69/157 - Esters d'acide acétique de composés monohydroxylés d'alcools non saturés contenant des cycles aromatiques à six chaînons
• C07C 69/68 - Esters d'acide lactique
• C07C 69/63 - Esters contenant des atomes d'halogène d'acides saturés
• C07C 233/65 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant les atomes d'azote des groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués

Abrégé

The present disclosure pertains to a combination of specific benzene sulfonamide thiazole compounds with an anticancer treatment for use in the treatment of cancer in a patient in need thereof. Using several cancer cell models, the present inventors have shown that a combined therapy using specific benzene sulfonamide thiazole compounds and an anticancer treatment such as an 5 immunotherapeutic agent, a chemotherapeutic agent or targeted therapies allows specifically triggering immune cell death markers, thereby potentializing the effects of each compound alone.

Classes IPC  ?

• A61K 31/428 - Thiazoles condensés avec des carbocycles
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 31/4523 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61P 33/00 - Agents antiparasitaires

Abrégé

The present invention relates to GLP-1 receptor agonist compounds having an additional agonist activity over the GIP receptor and/or an agonist activity over the glucagon receptor and/or an antagonist activity over the GIP receptor for use in the treatment of joint diseases and/or joint pain and selected from the group comprising retatrutide, tirzepatide, orforglipron, mazdutide, efinopegdutide, froniglutide, maridebart cafraglutide, survodutide, efpeglenatide, ecnoglutide, efocipegtrutide and UBT251. The invention also relates to a pharmaceutical composition comprising at least one of the above mentioned GLP-1 receptor agonist compound, and a pharmaceutically acceptable excipient, for use in the treatment of joint diseases and/or joint pain.

Classes IPC  ?

• A61K 38/26 - Glucagons
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Here, the inventors have developed a spectral flow cytometry assay to measure heme biosynthesis. By using this new assay on melanoma cell lines, they observed a direct correlation between high PPIX levels in differentiated MITFhighcells and a protection against ferroptosis. Conversely, cell lines with low PPIX levels were associated with a dedifferentiated MITFlow phenotype enriched in stem cell markers and more sensitive to ferroptosis inducers. They also found that inhibition of PPIX biosynthesis in differentiated melanoma cells synergizes with iron overload to induce lipid peroxidation and tumor cell death. Finally, they show that decreased levels of PPIX linked to increased ferroptosis sensitivity can be acquired in vivo in melanoma tumors that relapse after anti-MAPK targeted therapies. The present invention relates to a method of determining whether a subject has or is at risk of having melanoma ferroptosis sensitivity and targeted therapy resistance comprising i) determining the level of protoporphyrin IX (PPIX) in a biological sample obtained from the subject and ii) comparing the level determined at step i) with a predetermined reference value: wherein if the level of the PPIX determined at step (i) is lower than the predetermined reference value is indicative that the said patient is having melanoma ferroptosis sensitivity and targeted therapy resistance or wherein if the level of the PPIX determined at step (i) is higher than the predetermined reference value is indicative that the said patient is having melanoma ferroptosis resistance and targeted therapy sensitivity. The present invention also relates to a method for treating resistant melanoma in a subject in need thereof comprising a step of administering said subject with a therapeutically effective amount of a ferroptosis inducer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to combination of (i) a methionine-depleting composition, of (ii) one or more methionine synthase inhibitors and of (iii) optionally one or more further agent selected from a chemotherapeutic agent, a radiotherapeutic agent or an immunotherapeutic agent against cancer, for its use for treating a cancer, especially in cancers involving the presence of methionine-independent cancer cells

Classes IPC  ?

• A61K 38/51 - Lyases (4)
• A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

The present invention relates to FGF10 for use in the treatment of heart diseases.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A01K 67/0275 - Vertébrés modifiés génétiquement, p. ex. transgéniques
• C12N 15/86 - Vecteurs viraux

Abrégé

Myotonic Dystrophy type 1 (DM1) is an inherited disease characterized by multi-systemic symptoms, particularly in skeletal muscles (progressive weakness and atrophy, myotonia). The inventors screened 7 500 bioactive compounds for their ability to improve the myogenic fusion and reduce the molecular hallmarks of DM1 skeletal muscle cells. The inventors found that five compounds, all inhibiting HDAC6, a cytoplasmic histone deacetylase, were effective at the micromolar range in normalizing the myogenic fusion, reducing the number of nuclear foci of mutant DMPK mRNA, decreasing the expression level of DMPK mRNA, restoring the splicing of several genes, and increasing the acetylation of SMAD3, a transcription factor involved in muscle development. The effects of HDAC6 inhibitors were observed both in immortalized and hiPSC-derived skeletal muscle cells from DM1 patients, and in different stages of differentiation. Thus, the present invention relates to the use of selective HDAC6 inhibitors for the treatment of DM1.

Classes IPC  ?

• A61K 31/17 - Amides, p. ex. acides hydroxamiques ayant le groupe N-C(O)-N ou N-C(S)-N, p. ex. urée, thiourée, carmustine
• A61K 31/42 - Oxazoles
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
• A61K 31/505 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime
• A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire

Abrégé

aaaaaaa filtered images.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• G01S 15/89 - Systèmes sonar, spécialement adaptés à des applications spécifiques pour la cartographie ou la représentation
• A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores

Abrégé

Circadian rhythms control the diurnal nature of many physiological, metabolic and immune processes. The inventors hypothesized that age-related impairments in circadian rhythms are associated with high susceptibility to bacterial respiratory tract infections. The diurnal control of Streptococcus pneumoniae infection is impaired in elderly mice. A lung circadian transcriptome analysis revealed that aging alters the daily oscillations in the expression of a specific set of genes and that some pathways that are rhythmic in young-adult mice are nonrhythmic or time-shifted in elderly mice. In particular, the circadian expression of the clock components Rev-erb-α, and Rev-erb-β to a lesser extent, altogether with apelin/apelin receptor were altered in elderly mice compared to young mice. In young mice, the inventors discovered that novel interaction between Rev-erb and the apelinergic axis controls host defenses against S. pneumoniae via alveolar macrophages. Pharmacological repression of Rev-erb-α and/or Rev- erb-β in elderly mice resulted in greater resistance to pneumococcal infection. Thus, the present invention relates to the use of Rev-erb antagonists for the treatment of lung infections.

Classes IPC  ?

• A61K 31/4725 - Isoquinoléines non condensées, p. ex. papavérine contenant d'autres hétérocycles
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/00 - Agents anti-infectieux, c.-à-d. antibiotiques, antiseptiques, chimiothérapeutiques
• A61P 31/04 - Agents antibactériens
• A61P 31/10 - Antifongiques
• A61P 31/12 - Antiviraux

Abrégé

The present invention relates to the field of treat age-related cognitive declines. In this study, the inventors report that GPR158, which localizes at the PC, is required for OCN- dependent autophagy induction in hippocampal neurons. Consistently, the mobilization of key autophagy players by OCN in hippocampal neurons requires core PC-proteins. In aged hippocampi, neuronal PC present an abnormal morphology, correlated with a reduction of the major core ciliary proteins levels. Conversely, restoration of their levels in aged hippocampi is sufficient to improve autophagy and cognitive deficits. Lastly, they show that core PC-proteins are required to integrate the rejuvenating effects of OCN in the hippocampus, thereby ameliorating age-related cognitive deficits. Altogether, these findings demonstrate a new paradigm for the neuron/systemic milieu communication and significantly advance our understanding of the regulatory mechanism mediating the rejuvenating effects of the pro-youth blood factor, OCN, in hippocampal neurons. This study also provides the foundation for novel therapeutic strategies to treat age-related cognitive decline, as well as neurological deficits in ciliopathies. Thus, the present invention relates to an activator of the primary cilia (PC) for use in the restoration and/or improvement of cognitive functions in a subject in need thereof.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 31/365 - Lactones
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• C07K 14/46 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The present application relates to peptides derived from the transmembrane domain of Plexin-A1 that inhibits Neu-ropilin-1/Plexin-A1 heterodimerization. These peptides neutralize the inhibitory effect of Sema3A on cell migration and angiogenesis, and may be useful for the treatment of diseases associated with Sema3A and/or Neuropilin-1/Plexin-A1 activity, such as demyelinating diseases and diseases associated with abnormal angiogenesis such as cancer.

Classes IPC  ?

• C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence

Abrégé

The device comprises a substrate comprising a first zone (1) on which is absorbed a protein capable of binding to a first membrane molecule and comprising a second zone (2), on which an antibody is absorbed, targeting a second membrane molecule, the first zone and the second zone extending together in length over a dimension comparable to the length of a cell.

Classes IPC  ?

• G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a topcially-acting pain-relief pharmaceutical composition for topical use, comprising, as an active ingredient, one or more natural or synthetic peptides from the ω-conotoxin family, or one or more functionally active natural or synthetic variants thereof, the composition being intended for use in a method for treating acute or chronic nociceptive, neuropathic or nociplastic pain, such as intense chronic inflammatory and neuropathic pain, and being characterised in that it is administered locally, via the skin, close to and at the site of the free endings in the skin of the nociceptors that innervate the skin.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Here, the inventors use genomics to discover a new family of lanthipeptides from Actinobacteria dedicated to anti-phage defense. They demonstrate that a specific family of metabolic pathways that produce unknown class I lanthipeptides are encoded near known anti-phage defense systems or within mobile genetic elements, indicating their anti-phage function. Furthermore, the inventors show that the heterologous expression of these pathways in Streptomyces albus (a model strain of Actinobacteria) confers anti-phage defense. The experimental results show that different lanthipeptides of this family confer a selective protection against phages, without compromising the cell viability. The inventors also have identified a specific regulatory system that controls the expression of "defensive lanthipeptides" in Actinobacteria and use this to demonstrate their anti-phage function in a native strain. Finally, the inventors explore the anti-phage mechanism of action of these compounds. Thus the present invention relates to a new class of anti-phage natural peptides.

Classes IPC  ?

• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
• C07K 7/54 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle

Abrégé

Glycated Hb was measured in reticulocytes (RNA-positive cells) and was correlated to a decrease in RNA fluorescence intensity in a Log-linear dependent manner, with no statistically significant differences in slope or in the ordinate of the origin between individuals. The loss of RNA fluorescence intensity in reticulocytes observed by flow cytometry is directly related to the time they spend in circulation and consequently to their lifespan. By setting the time that reticulocytes spend to mature in the blood circulation and because the relation between the decrease in log RNA fluorescence intensity and the increase in log HbA1c fluorescence intensity is linear, the inventors are able to calculate the increase in HbA1c fluorescence intensity depending on the time and thus to determine the mean half-life of a RBC population. This new tool is noninvasive and requires only one single time point measurement. The present invention relates to a method for in vitro determination of the age of red blood cells of a set of red blood cells by using intracellular glycated hemoglobin measurement by flow cytometry and by using a standard curve generated from glycated hemoglobin measurement in reticulocyes.

Classes IPC  ?

• G01N 33/72 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les pigments du sang, p. ex. l'hémoglobine, la bilirubine
• G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins

Abrégé

The present invention provides fusion molecules comprising the extracellular domain of CSF-1R which contains a specific single amino acid mutation. Such fusion molecules are capable of efficiently binding both CSF-1 and IL-34. The present invention also provides the use of such fusion molecules, or pharmaceutical compositions thereof, as therapeutic agents, in particular in the treatment of cancers, neurodegenerative diseases, autoimmune diseases, and allergic diseases, or in the prevention or inhibition of transplant rejection.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion

Abrégé

The invention relates to the field of Bipolar Disorder. In a recent study, the inventors performed the first genome-wide analysis of DNA methylation profiles among individuals with BD type I assessed for their response to long-term treatment with Li and identified differentially methylated regions (DMRs) between GR and NR, selecting only methylation differences that were not impacted by co-prescribed treatments that are -by definition- more frequent in NR (Marie-Claire et al., 2020). They then used MS-HRM to validate 3 DMRs that discriminated GR from NR in an extended sample of 70 individuals with BD-I. They also showed, in an independent sample that combining a few clinical variables with the three DMRs improved the performance of these MS-HRM-based biomarkers to discriminate groups (Marie-Claire et al., 2023). In the present study, they improved the performance of the combination of MS-HRM- based biomarkers and clinical predictors to discriminate individuals that benefited from Li treatment (GR and PaR) from those who did not (NR) in a retrospective sample. Thus, the present invention relates to a method for predicting whether a patient achieves a response with a treatment of Bipolar Disorder (BD) comprising determining, in a biological sample from the patient the epigenetic profile of at least 4 of the differentially methylated regions (DMRs) selected in the list consisting of DMR7291, DMR17107, DMR17978, DMR24332, DMR63769, DMR79888, DMR106540 and DMR81023.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The present invention relates to a newly identified skin-tropic subset of Tscm that expresses the cutaneous homing marker CLA+. The identification of this new cell population of skin homing Tscm opens up new cell therapy strategies to treat cutaneous diseases, in particular cutaneous cancers such as Merkel cell carcinoma.

Classes IPC  ?

• C12N 5/078 - Cellules du sang ou du système immunitaire

Abrégé

It is disclosed a method processing imaging data of a patient having cancer, for instance lymphoma, comprising:—Providing three-dimensional imaging data of the patient,—computing from said three-dimensional imaging data, at least one two-dimensional Maximum Intensity Projection image. corresponding to the projection of the maximum intensity of the three-dimensional imaging data along one direction onto one plane,—extracting a mask of the MIP image corresponding to cancerous lesions by application of a trained model. Using the extracted mask it is possible to compute one or more cancer prognosis indicators.

Classes IPC  ?

• G06T 7/00 - Analyse d'image
• G06N 3/0455 - Réseaux auto-encodeursRéseaux encodeurs-décodeurs
• G06N 3/0464 - Réseaux convolutifs [CNN, ConvNet]
• G06T 3/06 - Mappage topologique de structures de dimension plus élevée sur des surfaces de dimension moins élevée
• G06V 10/75 - Organisation de procédés de l’appariement, p. ex. comparaisons simultanées ou séquentielles des caractéristiques d’images ou de vidéosApproches-approximative-fine, p. ex. approches multi-échellesAppariement de motifs d’image ou de vidéoMesures de proximité dans les espaces de caractéristiques utilisant l’analyse de contexteSélection des dictionnaires
• G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p. ex. l’édition
• G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux

Abrégé

The present invention relates to aptamers that specifically bind to the extra-cellular domain of alpha7/beta1 integrin dimers, conjugates or particles comprising said aptamers, in muscles cells such as skeletal muscle fibres and satellite cells, or in cells aberrantly expressing said domain e.g. tumour cells such as rhabdomyosarcoma (muscle-derived tumours), or glioblastoma cancer stem cells, as well as conjugates comprising said aptamers, therapeutic or diagnostic compositions comprising said conjugates or said aptamers, and their use as a medicament and in diagnostic methods.

Classes IPC  ?

• C12N 15/115 - Aptamères, c.-à-d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider

Abrégé

Inventors demonstrated that an epigenetic regulator CBX3 antagonizes IFNγ signalling via directly repressing the transcription of two key interferon-stimulated immune genes, STAT1 and PD-L1. The key role of CBX3 in repressing STAT1 and PD-L1 transcription suggests that CBX3 is an important checkpoint to control immune genes' activation in response to different ligands' stimulation, such as the important immune modulator IFNγ, which placed CBX3 in a key position to keep colon immune homeostasis. This role placed also CBX3 in a key position to keep colon immune homeostasis. These studies have started to reveal a new role of CBX3 in controlling the colon epithelium inflammatory response, in addition to its classical role in the formation and stabilization of heterochromatin. Particularly, low CBX3 expression is associated with better CRC patients' overall survival. Corresponding to this result, CBX3 depletion makes IFNγ-insensitive CRC cells dramatically regain IFNγ sensitivity, which significantly increases CRC cells' chemosensitivity under IFNγ stimulation. Accordingly, the invention relates to a Chromobox protein homolog 3(CBX3) inhibitor for use in the treatment of cancer in a subject in need thereof.

Classes IPC  ?

• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61K 31/513 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p. ex. cytosine
• A61K 38/21 - Interférons
• A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline

Abrégé

The invention relates to the human protein Family with sequence similarity 118 member B (FAM118B). In particular, the present invention relates to the activation, or the inhibition of the activity or effect provided by FAM118B, for modulating the inflammatory response. In particular, it is provided the use of activator of FAM118B, or an activator of the biological effects provided by FAM118, for inducing, sustaining, or enhancing an inflammatory process, in particular an inflammatory process associated with a cancer, a bacterial infection, or a viral infection. In particular, it is also provided the use of an inhibitor of FAM118B, or an inhibitor of the biological effects provided by FAM118B, for inhibiting, or reducing an inflammatory process, more particularly for inducing the resolution of an inflammatory process.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
• A61P 7/00 - Médicaments pour le traitement des troubles du sang ou du fluide extracellulaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 35/00 - Agents anticancéreux
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

A tracking system and a method for 3D tracking of a medical device, equipped of at least one ultrasound sensor, inside an anatomical region of a subject having at least one layer of a first tissue type at least partially surrounding a volume having at least one second tissue type, wherein the properties of ultrasounds propagation in the first and second tissue type are different.

Classes IPC  ?

• A61B 8/08 - Applications cliniques
• A61B 34/20 - Systèmes de navigation chirurgicaleDispositifs pour le suivi ou le guidage d'instruments chirurgicaux, p. ex. pour la stéréotaxie sans cadre
• A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures

Abrégé

EVs are being recognized as vectors for drug delivery. In particular. EV loading with targeting and therapeutic agents brings along an interesting opportunity to translate EVs into a bio-mimetic selective delivery system. Indeed. EVs constitute a physiological carrier being potentially less immunogenic than artificial delivery vehicles. The inventors now developed a novel method to control the loading of a cargo into EVs on demand. These EVs are equipped, if necessary, with non-viral fusogen, therefore enhancing EV-cargo delivery into acceptor cells. To acutely measure this process, they follow the fate of a luciferase-tagged cargo. Cargo loading was enabled through a drug-reversible inducible dimerization system. Briefly, donor cells were transfected with plasmids encoding for FKBP-tagged CD63, a classical membrane EV marker, and FRB-Nanoluciferase (NLuc) that is normally cytosolic. Upon addition of the dimerizing drug. FRB-Nluc interacts with FKBP-CD63 and is recruited into secreted EVs. This is accompanied by an enhanced delivery into acceptor cells. This phenomenon can be further enhanced when EVs are equipped with syncitin1, a mammalian fusogenic protein that trigger fusion between EV membrane and the plasma membrane of acceptor cells. Using this novel process, the inventors further demonstrated that the catalytic domain of the Diphteria toxin (DTA), that is responsible for protein synthesis inhibition and ultimately cell death, can be delivered to acceptor cells via functionalized EVs. This led to protein synthesis inhibition and death of acceptor cells. This novel method and the derived applications promise to open new doors in precision care medicine, especially when EVs will be equipped with antibodies raised against cell specific antigens.

Classes IPC  ?

• A61K 9/50 - Microcapsules
• A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• C12N 9/22 - Ribonucléases
• C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées

Abrégé

An elastography apparatus is described that is designed to assist in magnetic resonance elastography of the head of an examination object. The elastography apparatus comprises a first support element which is designed to be positioned within a radiofrequency receiving coil unit and a vibration generator which is designed to generate mechanical waves. The first support element has a first recess for receiving the vibration generator, the first support element has a second recess for receiving the head, and the first recess is so shaped as to at least partially enclose the vibration generator in a custom-fit manner and the vibration generator is arranged at least partially within the first recess.

Classes IPC  ?

• G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique

Abrégé

The present invention relates to lipid nanoparticle loaded with antitumoral agent and functionalized to target immunosuppressive cells. Inventors developpe valrubicin-loaded immunoliposomes (Val-ILs). A small amount of valrubicin incorporated into Val-ILs induces leukemia cell death in vivo, suggesting that Val-ILs could be used to treat acute leukemia cells. Inventors also demonstrated that Val-ILs could reduce the risk of contamination of CD34+ hematopoietic stem cells by acute leukemia cells during autologous peripheral blood stem cell transplantation. They also highlighted the potential of Val-ILs to target immunosuppressive cell populations in the spleen. The most efficient Val-ILs were found to be those loaded with CD11b,CD223, CD64, TIM1, CD200R3, CD204, CD49b, VEGFR2 and SIGLECF antibodies. This study provides the effectiveness and ease of preparation of Val-ILs as a novel nanoparticle technology. In the context of cancers, Val-ILs have the potential to be used as a precise and effective therapy based on targeted vesicle-mediated cell death.

Classes IPC  ?

• A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to the use of Melanoma Differentiation-Associated protein (MDA5) inhibitors for enhancing the number of p16highin vitroin vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is moreover herein reported that p16highimmune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. Mechanistically, it is shown that inhibition of MDA5 induces an increase in p16high immune cells subsets that, in turn, establishes a low adenosine environment and disease tolerance. The present invention also relates to a pharmaceutical composition comprising immune cells such as CAR-T cells in which the MDA5 expression and/or activity is inhibited, and its use for various therapeutic purposes.

Classes IPC  ?

• A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• C12N 9/14 - Hydrolases (3.)
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens

Abrégé

22 ratio, improving metabolic adaptation to the HFD challenge. Our results highlight the role of mitochondrial daily rhythms in the pathophysiology of obesity and open avenues for chronopharmacological treatments targeting these rhythms. Thus, the present invention pertains to a method for treating or preventing obesity in a subject in need thereof. This method includes administering to the subject, at a specific time of the circadian rhythm, a therapeutically effective amount of a dihydroorotate dehydrogenase inhibitor that exhibits an inhibitory duration of less than 24 hours, and more specifically, a short half-life of less than 24 hours.

Classes IPC  ?

• A61K 31/4196 - 1,2,4-Triazoles
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 3/04 - AnorexigènesMédicaments de l'obésité

Abrégé

The present invention relates to a CXCR4 inhibitor compound for use in the treatment of a severe acute respiratory distress syndrome (sARDS), wherein the sARDS is characterized by a dysregulation of NETosis which may be measured by the plasmatic levels of cDNA, citrullinated histone H3, neutrophil elastase, interleukin-8, myeloperoxidase-DNA complexes and/or calprotectin. The present invention also relates to a method of prognostic of severe ARDS, a pharmaceutical composition for use in the treatment of severe acute respiratory distress syndrome (ARDS), a kit of prognostic of severe ARDS in a subject and the use of NETosis biomarkers.

Classes IPC  ?

• A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
• A61K 31/4402 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 2, p. ex. phéniramine, bisacodyl
• A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
• A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61K 31/4427 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques
• A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes

Abrégé

Developing an effective HIV-1 vaccine is contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, the inventors aimed to refine Langerhans cells (EC) targeting by designing three Env monochains instead of 2 (EC3. Env3) mimicking natural Env conformation. The inventors demonstrated that EC3. Env3 construct (i) elicited a rapid and potent Env-IgG response, (ii) enhanced the avidity of anti-Env IgG that was accompanied by a marked expansion of Tfh and GC B cells and (iii) swiftly induced the formation of structured germinal centers in dLN, indicative of a robust immune response. Finally, significant Tier-1 NeutAb induction was observed in rabbits immunized with the construct. In conclusion, HIV Env antigen can be adaptively targeted to LC as a timer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such a construct as LC targeting HIV-1 vaccines.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/12 - Antigènes viraux
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• C07K 14/005 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de virus
• C07K 14/16 - HIV-1
• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV

Abrégé

The present invention relates to the use of a STING agonist, of a TLR5 agonist or of a TLR7 agonist for enhancing the number of p16highin vitroin vitro or in a patient in need thereof, in particular to extend health span and protect tissues against aging. It is also herein reported that p16highimmune cells surprisingly play a key role in establishing disease tolerance, and can be useful for counteracting different lethal conditions, including LPS-induced sepsis, acute lethal SARS-CoV-2 infection, cancer and ionizing irradiation. The present invention thus relates to a pharmaceutical composition comprising autologous or heterologous p16highimmune cells such as p16high CAR-T cells, and its use for various therapeutic purposes. These cells are preferably obtained by contacting them with a STING agonist, a TLR5 agonist and/or a TLR7 agonist.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Monitoring active disease or progressive disease under therapy in chronic lymphocytic leukemia (CLL) represents a challenge to earlier and better adapt therapeutic strategy, notably in the era of targeted therapies in which minimal residual detection or mutations are sometimes not associated to poor clinical outcome. By following CLL patients before treatment (Binet stages A and B/C) or during targeted therapy, the Inventors developed a new flow cytometric method, based on CD69, CD49d, CD20 and CD279 expression at the surface of CD19+/CD5+ B leukemic cells. Analyses of these markers alone or in combination show that CD69/CD49d/CD20/CD279 co-expression (quadruple population, QP) > 0.5% is the best criterion predicting CLL active disease or progression under therapy. This new flow cytometry immunophenotyping could help clinicians to monitor CLL evolution and quickly adapt their therapeutic strategy. Accordingly, the present invention relates to an ex vivo method for predicting active Chronic Lymphocytic Leukemia (CLL) or progressive CLL under therapy in a subject suffering from CLL, comprising the step of quantifying a population of CD69+/CD49d+/CD20+/CD279+ cells in a sample obtained from the subject.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The invention relates to a modified myeloid cell comprising a cytokine chimeric receptor (CCR), wherein said CCR comprises an extracellular domain comprising an extracellular domain of a cytokine receptor which binds soluble molecules present in the tumor microenvironment (TME); a transmembrane domain; and an intracellular signaling domain comprising CD40 cytotail, CD3zeta intracellular domain and/or STING or one of its fragments. The invention also relates to a modified cell comprising a CCR and a transgene coding for a cytokine. The invention also relates to therapeutic uses thereof and to methods and pharmaceutical compositions for the treatment of cancer.

Classes IPC  ?

• A61K 40/00 - Immunothérapie cellulaire

Abrégé

The present invention relates to a disposable sensor (1) for measuring at least one of the quinolinate concentration and the tryptophan concentration in real time in human urine: - a molecularly imprinted polymer, MIP, support (11) comprising a polymer matrix (110), at least one of a first set of cavities (112) adapted to measure the quinolinate concentration and a second set of cavities (113) adapted to measure the tryptophan concentration within the polymer matrix (110); and - an optical fibre (12) coated with the MIP support (11). It also relates to a system (3) comprising same, a method for making same, and a method for measuring at least one of the quinolinate concentration and the tryptophan concentration using same.

Classes IPC  ?

• G01N 21/64 - FluorescencePhosphorescence
• G01N 21/77 - Systèmes dans lesquels le matériau est soumis à une réaction chimique, le progrès ou le résultat de la réaction étant analysé en observant l'effet sur un réactif chimique
• G01N 33/493 - Analyse physique de matériau biologique de matériau biologique liquide d'urine

Abrégé

The invention relates to an in vitro method for classifying a subject afflicted with a cancer as suffering from a cancer with (at risk of) a metabolic reprograming towards fatty acids oxidation including a step of assaying the activation of RelB in a tumor sample form said cancer. The inventor indeed identified the pivotal role of RelB in energy metabolism and more particularly mitochondrial respiration and fatty acid oxidation. Accordingly, the invention also relates to inhibitors of RelB activity or expression, as well as of lipid metabolism for use in the treatment of cancers showing an activated RelB.

Classes IPC  ?

• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

Early diagnosis of cardiovascular diseases can potentially cure subjects and save innumerable lives. Diagnosis and treatment of subjects at early stages by cardiologists remain a challenge. Here, the inventors have measured baseline sTREM-1 (triggering receptor expressed on myeloid cells-1) in 10,000 initially healthy participants without prevalent cardiovascular disease (CVD) from the Paris Prospective Study 3 (PPS3). They have quantified the association and predictive value of baseline sTREM-1 for incident CVD events over 10 years of follow-up. The analysis reveals strong, significant and independent association with incident CVD events combined and its subtypes (coronary heart disease, stroke, peripheral artery diseases, and heart failure). Furthermore, adding sTREM-1 to existing risk prediction algorithms such as SCORE2 or the US pooled risk equation improved the discrimination capacity of these models in a significant and more importantly in a clinically meaningful manner, including among those at moderate CVD risk. Furthermore, the inventors have examined CVD events such as aneurysm, arrythmias and thromboembolic events. Given the ongoing development of pharmacological molecules blocking blood sTREM-1, the inventors believe these findings support future intervention trials testing to which extent sTREM-1 could be a relevant target for the primary prevention of CVD in the general population.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention pertains to the field of cancer treatment by Immune Checkpoint Inhibitors (ICIs) and to the risk stratification and personalized treatment of patients having ICI-induced myotoxicity.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne

Abrégé

The invention concerns a carbon monoxide-releasing molecule (CORM) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis in a subject. More particularly, the invention concerns a carbon monoxide-releasing molecule (CORM) or composition thereof for use in the treatment or the prevention of an intestinal dysbiosis, preferably a caecum and/or colon dysbiosis in a subject, wherein the carbon monoxide-releasing molecule or composition thereof is administered orally.

Classes IPC  ?

• A61K 31/28 - Composés contenant des métaux lourds
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier

Abrégé

The present disclosure relates to a method of performing 3D Magnetic Resonance Imaging including applying a magnetic gradient field that causes a concomitant field Bc. A further step of the method includes determining phase accruals due to the self-squared terms of the concomitant field Bc and phase accruals φxz, φyz due to the cross terms of the concomitant field Bc based on an encoding matrix that accounts for the different possible sign combinations of the applied magnetic gradients.

Classes IPC  ?

• G01R 33/565 - Correction de distorsions d'image, p. ex. dues à des inhomogénéités de champ magnétique
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G01R 33/385 - Systèmes pour produire, homogénéiser ou stabiliser le champ magnétique directeur ou le champ magnétique à gradient utilisant des bobines de champ magnétique à gradient

Abrégé

The invention relates to methods of diagnosing kidney cancer and to kits for diagnosing kidney cancer.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

MYCC-MYCC-MYC. The present invention also relates to a nucleic acid encoding said TCR, a vector comprising the nucleic acid, and a cell, preferably a T cell, comprising the same. Another aspect of the present invention is a cell, preferably a T cell, comprising said TCR for use as a medicament or for treating cancer.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• C07K 14/725 - Récepteurs de lymphocytes-T
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine

Abrégé

In the present invention, inventors demonstrate that prenatal excess of anti-Müllerian hormone triggers PCOS-like impairment in female sexual behavior in mice. Sexual dysfunction in PCOS-like mice is associated with decreased expression of neuronal nitric oxide synthase (nNOS) neurons in different hypothalamic regions known to be involved in female sexual behavior: rostral periventricular area of the third ventricle (RP3V), ventromedial nucleus of the hypothalamus (VMH), and arcuate nucleus (ARN) during estrus. Chemogenetic inhibition of nNOS neuronal activity in the ventromedial nucleus of the hypothalamus of control adult females recapitulates PCOS-like sexual dysfunction. Of clinical relevance, administration of nitric oxide (NO) donor rescues normal sexual behavior in PCOS-like mice. Accordingly, the present invention relates to invention relates to Nitric Oxyde (NO) agent for use in the prevention or the treatment of sexual dysfunction associated with Polycystic Ovary Syndrome (PCOS) or with Hypoactive Sexual Desire Disorder (HSDD) in a subject in need thereof.

Classes IPC  ?

• A61K 33/00 - Préparations médicinales contenant des ingrédients actifs inorganiques
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuelsContraceptifs

Abrégé

The present invention generally relates to the field of genome engineering (gene editing), and more specifically to ex vivo gene therapy for the treatment of Activated PI3kinase Delta Syndrome type 1 (APDS1) related to PIK3CD gene. Particularly, the present invention pertains to the treatment of PIK3CD deficiency in hematopoietic stem cells (HSCs) and/or T-cells. The present invention provides means and methods for genetically modifying HSCs and/or T-cells involving gene editing reagents, such as TALE-nucleases, that specifically target an endogenous PIK3CD locus, at least in the PIK3CD allele comprising at least one APDS1-associated mutation, thereby allowing the restoration of the normal cellular phenotype. The present invention also provides engineered PIK3CD-edited HSCs and engineered PIK3CD-edited T-cells comprising at least one exogenous sequence comprising a nucleic acid sequence encoding a functional PI3Kδ protein which is integrated in said HSCs' or T-cells' genome into a PIK3CD locus, in a non-functional PIK3CD allele, resulting in the expression of a functional PI3Kδ polypeptide. The present invention further provides populations of cells comprising said engineered HSCs or T-cells, pharmaceutical compositions comprising said engineered cells or populations of cells, as well as their use in gene therapy for the treatment of APDS1.

Classes IPC  ?

• A61K 40/41 - Antigènes de vertébrés
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome

Abrégé

In a method for performing Magnetic Resonance Elastography (MRE) more efficiently may include providing a periodical vibration signal for exciting mechanical vibrations within an object to be examined with a vibration period, sampling the vibration signal with a sampling period corresponding to a natural number including zero of vibration periods plus a fixed time delay, and performing three motion encoding gradients for magnetic resonance acquisition in each sampling period. The fixed time delay multiplied with a sampling number may be equal to the vibration period. The sampling number may be a natural number greater than two.

Classes IPC  ?

• G01R 33/563 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne de matériaux en mouvement, p. ex. angiographie à écoulement contrasté
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
• A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
• G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne

Abrégé

The invention relates to a method for the temporal calibration of a phylogenetic tree by means of digital processing, and comprises: - receiving, in digital format, a set of dated events involving the isolation or transmission of a pathogen, and a set of events to be dated involving the isolation or transmission of the pathogen, organised in the form of a phylogenetic tree following a traversal order from the root to the leaves. A plurality of events have a date to be determined; - forming a Hessian matrix of a logarithmic objective function F of a molecular clock model of the pathogen, defining the relationship between the genetic distances, the dates, and the durations between the events, wherein the Hessian matrix H comprises what is referred to as a local block T defining the branches between the events on the phylogenetic tree. The block T has a size proportional to the number of events on the phylogenetic tree for which the date is to be determined; - identifying the dates to be determined by means of Newton's optimisation method.

Classes IPC  ?

• G16B 10/00 - TIC spécialement adaptées à la bio-informatique évolutive, p. ex. construction ou analyse d’arbre phylogénétique

Abrégé

Host protection against infectious diseases involves complex cross-regulation between the immune system and the nervous system. However, the molecular mechanisms behind this regulation remain poorly understood, particularly in the context of viral infections. Using a mouse model of herpes simplex virus 1 (HSV-1) infection, the inventors demonstrate a role of primary sensory neurons in regulating the antiviral innate and adaptive immune response in the skin and the skin draining lymph node. The inventors show that an excess of neutrophil myeloperoxidase (MPO) activity in the skin inhibits the dendritic cell response, thereby limiting the priming of HSV-1-specific CD8+T cells in the skin draining lymph node. This study reveals novel site-specific neuroimmune regulatory mechanisms controlling antiviral host defense, opening up novel therapeutic perspectives. Thus, the present invention relates to a method of promoting CD8+ T-cell responses in a subject in need thereof comprising administering to the patient a therapeutically effective amount of a myeloperoxidase inhibitor.

Classes IPC  ?

• A61K 31/136 - Amines, p. ex. amantadine ayant des cycles aromatiques, p. ex. méthadone ayant le groupe amino lié directement au cycle aromatique, p. ex. benzène-amine
• A61K 31/15 - Oximes (C=N-O-)Hydrazines ( N-N)Hydrazones (N-N=)
• A61P 31/04 - Agents antibactériens
• A61P 31/12 - Antiviraux
• A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to an in vitro method for establishing the prognosis of a subject diagnosed as suffering or having suffered from a diffuse large B-cell lymphoma and including: - an identification step of at least two markers comprising 2-aminobutyrate or its acid derivative thereof and LDL-1 lipoprotein optionally in combination with at least one marker selected from : 2-hydroxybutyrate or its acid derivative thereof, 3-hydroxybutyrate or its acid derivative thereof, LDL-2 lipoprotein, LDL-1-CH lipoprotein, LDL-1 lipoprotein phospholipids, the Apo-B subfraction of LDL-1 lipoprotein, LDL-1 lipoprotein triglycerides, LDL-2 lipoprotein triglycerides, LDL-3 lipoprotein triglycerides, formic acid and acetyl acetic acid, identifying said at least two markers being the prognosis of, or a risk of, a bad clinical course of the diffuse large B-cell lymphoma in the subject.

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• G01N 33/92 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des lipides, p. ex. le cholestérol

Abrégé

The present invention relates to the treatment of inflammation. Here, the inventors generated a mouse model able to trace the expression of MrgprE and to interrogate its function, in vivo. They identified the cells expressing MrgprE notably among leukocytes. The MrgprEMutmice do not present any abnormality especially in the immune and peripheral nervous systems. Interestingly, the ablation of MrgprE expression decrease significantly asthma associated airway hyperresponsiveness and inflammation; symptoms that are restored when MrgprE is expressed by Nav1.8+ sensory fibers. In the context of asthma, an inhibitor of MrgprE could have a dual mode of action preventing both airway hyperresponsiveness and inflammation. Thus, the present invention relates to a MRGPRE binding agent for use in the treatment of inflammatory disorders in a subject in need thereof.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 11/06 - Antiasthmatiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• C07K 16/08 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus

Abrégé

The invention relates to a microfluidic device (1) comprising a frame (32) and two opposite walls (16a,b), the two opposite walls (16a,b) and the frame (32) delimiting together a chamber (2): —the chamber (2) comprising a first zone (4) and a second zone (5), —the second zone (5) comprising a porous member (3) extending in the chamber (2) and comprising a first surface (9) and a second surface (10) opposite to the first surface (9), the first surface (9) separating the chamber (2) in the first zone (4) and in the second zone (5), —the frame (32) comprising at least a first and a second sets of ports (11, 12, 13, 14), the first set of port comprising at least two ports (11, 12) arranged in the frame (32) for fluid circulation within in the first zone (4) and the second set of ports comprising at least two ports (13, 14) arranged in the frame (32) for fluid circulation within the second zone (5), and—the two ports (13, 14) of the second set of ports being open (i) in a microchannel (15) extending through the porous member (3), or (ii) in a cavity (19) arranged between the second surface (10) of the porous member (3) and the frame (32) of the chamber (2). The invention relates to microphysiological systems comprising a microfluidic device and cultured cells on the top surface of the hydrogel matrix. The microphysiological systems may be used to model biological surface or biological tissue at physiological interface comprising a luminal and a stromal compartments, such as colon, pancreas or skin tissue.

Classes IPC  ?

• C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse

Abrégé

Netherton syndrome (NS) is a rare recessive skin disorder caused by loss-of-function mutations in SPINK5 encoding the protease inhibitor LEKTI. NS patients present with typical ichthyosis linearis circumflexa (NS-ILC) or scaly erythroderma (NS-SE). Here the inventors employed a combination of several molecular profiling methods to comprehensively characterize the skin, immune cells and allergic phenotypes of NS-ILC and NS-SE patients. In particular, they studied a cohort of 13 NS patients comprising 9 NS-ILC and 4 NS-SE. Integrated multi-omics revealed abnormal epidermal proliferation and differentiation and IL-17/IL-36 signatures in lesion skin and in blood in both NS endotypes. This study thus identifies IL-17/IL-36 as predominant signaling axes in both NS endotypes and unveils molecular features distinguishing NS-ILC and NS-SE. In particular, blocking of IL36 signaling would therefore represent a novel therapeutic strategy for NS, in particular in NS-SE patients.

Classes IPC  ?

• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The invention pertains to a new computer-implemented method for processing an EEG signal, that makes it possible to extract information about cerebral damage in full-term babies, born in asphyxia context, for help in an indication for treatment of hypoxic-ischemic encephalopathy (HIE), by computing a power spectral density (PSD) of an EEG signal, transforming the PSD by a mathematical function, processing the transformed values by data binning, and creating a probability distribution of the durations of the binned values.

Classes IPC  ?

• A61B 5/374 - Détection de la répartition de fréquence dans les signaux, p. ex. détection des ondes delta, thêta, alpha, bêta ou gamma
• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

The present application concerns the use of endoprothesis covalently grafted with a fucoidan for treating aneurysms, in particular cerebral aneurysms, and their process for manufacturing the same. Improved healing of cerebral aneurysms was established in vivo on a rabbit model.

Classes IPC  ?

• A61L 31/16 - Matériaux biologiquement actifs, p. ex. substances thérapeutiques
• A61L 31/02 - Matériaux inorganiques
• A61L 31/10 - Matériaux macromoléculaires
• C08L 5/00 - Compositions contenant des polysaccharides ou leurs dérivés non prévus dans les groupes ou

Abrégé

The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof: wherein W, X, Y and Z are as defined, for use in the treatment of Multiple Myeloma (MM). A pharmaceutical composition including a pharmaceutical acceptable vehicle and at least a compound of formula (I) is also included.

Classes IPC  ?

• A61K 31/351 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle non condensés avec un autre cycle
• A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
• A61K 31/4162 - 1,2-Diazoles condensés avec des systèmes hétérocycliques
• A61K 31/4433 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
• A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
• A61K 38/07 - Tétrapeptides
• A61P 35/00 - Agents anticancéreux
• C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer

Abrégé

The present invention relates to the combination of a miR-17mimic and a miR-340 mimic for use for the prevention and/or treatment of cancer, in particular for the treatment of glioblastoma. In particular, said combination additionally comprises a miR-222 antagomiR.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to bispecific binding molecules, especially antibodies, targeting HER3 and another antigen selected from HER-2 and EGFR antigens, methods for the production of these molecules, compositions, and uses thereof.

Classes IPC  ?

• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/00 - Agents anticancéreux
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a compound of formula (I) and its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relates to the use of the induced immune cells in the prevention and/or treatment of immune-mediated diseases.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/15 - Cellules de la lignée des myéloïdes, p. ex. granulocytes, basophiles, éosinophiles, neutrophiles, leucocytes, monocytes, macrophages ou mastocytesCellules précurseurs myéloïdesCellules présentatrices d’antigène, p. ex. cellules dendritiques
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/13 - Lymphocytes B
• A61P 37/02 - Immunomodulateurs
• C07D 471/04 - Systèmes condensés en ortho
• C12N 5/0781 - Cellules BLeurs progéniteurs

Abrégé

Engraftment of hematopoietic stems cells (HSCs) is a potentially life-saving treatment therapy for various conditions including genetic blood cell diseases. In particular, the use of allogeneic HSCs to treat genetic blood cell diseases has become a clinical standard: HSCs can be modified ex vivo and transferred back to the recipient to produce functional, terminally-differentiated cells. There is a medical need for methods for assessing the exhaustion of HSCs for optimizing their therapeutic use, in particular in the context of gene therapy. The inventors performed a clinical trial of lentivirus-based gene therapy for the treatment of X-linked chronic granulomatous disease. Two patients showed stable engraftment and clinical benefits, whereas the other two progressively lost gene-corrected cells. Single-cell transcriptomic analysis revealed a significantly lower frequency of the most immature hematopoietic stem cell (HSC) in CGD patients, more pronounced in patients with defective engraftment. The two patients with defective engraftment presented a profound change in HSC status, a high interferon score, and elevated myeloid progenitor counts. The inventors used elastic-net logistic regression to identify a set of interferon genes and transcription factors that predicted the failure of HSC engraftment. They identified a set of 51 interferon genes and transcription factors that were upregulated specifically in P2 and P5 (including IFI44L, STAT2, IRF9, MX1, SAMD9L, and CEBPB) and that appeared to be predictive of defective HSC engraftment. Accordingly, the identified biomarkers can be very suitable for assessing the exhaustion of hematopoietic stems cells.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

Here, the inventors report the biochemical and functional characterization of a new PTM on a key ESCRT-III member and its impact during viral budding. They discovered that CHMP2B K6 plays a pivotal role in both abscission and HIV viral budding, highlighting the importance of the novel methylation event. Strikingly, expression of unmethylatable CHMP2B mutants (CHMP2B K6A, CHMP2B K6R) perturbed the localization of ESCRT-III at the ICB with delayed recruitment and distribution of CHMP2B to the cleavage site, ultimately leading to impeded abscission. They reported that expression of CHMP2B mutant bearing a specific lysine point mutation at position 6 drastically reduces the number of viral particles released into the supernatant. Additionally, this mutation impairs the infectivity of the produced virions. This is the first description of the antiviral effect of a point mutant of ESCRT-III proteins. Thus, the present invention relates to an isolated polypeptide derived from unmethylatable mutant CHMP2B and its uses for treating infection.

Classes IPC  ?

• A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
• C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A61K 38/03 - Peptides ayant jusqu'à 20 amino-acides dans une séquence indéterminée ou partiellement déterminéeLeurs dérivés
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides

Abrégé

The present invention relates to novel synthetic lipidic alkynylcarbinols, in particular as antibacterial agents, preferably against mycobacteria, and more preferably against species from the Mycobacterium tuberculosis complex, and also to therapeutic uses thereof. The present invention also relates to said compounds for use for the treatment of bacterial infections. The present invention further relates to the discovery of the pharmaceutical mechanism and bioactivity of these novel synthetic lipidic alkynylcarbinols.

Classes IPC  ?

• C07C 33/044 - Alcynediols
• C07C 33/048 - Alcools acycliques à liaisons triples carbone-carbone à liaisons double et triple
• C07C 33/05 - Alcools contenant des cycles autres que des cycles aromatiques à six chaînons
• C07C 33/12 - Alcools contenant des cycles autres que des cycles aromatiques à six chaînons contenant des cycles à cinq chaînons
• C07C 33/14 - Alcools contenant des cycles autres que des cycles aromatiques à six chaînons contenant des cycles à six chaînons
• C07C 33/30 - Alcools ne contenant que des cycles aromatiques à six chaînons dans la partie cyclique avec insaturation autre que celle des cycles aromatiques monocycliques

Abrégé

3184-3194219-22529-393184-3194219- 22529-3929-39 were significantly associated with an increased risk of developing MACE, CAD, CV death, and/or CV death. Thus the present invention refers to a method of predicting the risk of having or developing a cardiovascular event in a patient.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a module intended to be associated with a microscope for full-field optical coherence tomography microscopic imaging of at least one sample, the module comprising an interference device (4) comprising a non-polarising beam splitter element (10) for forming two arms when it is illuminated by a source, namely a “reference arm” associated with the reflection surface and an “object arm” associated with the sample, the device furthermore comprising: a first adjustment unit (11) arranged upstream of the non-polarising beam splitter element for allowing an illumination arm of the non-polarising beam splitter element to be modified during operation, and/or at least one second adjustment unit (18) arranged between the beam splitter element and the reflection surface for allowing the reference arm to be modified during operation.

Classes IPC  ?

• G02B 21/18 - Aménagements avec plus d'un parcours de lumière, p. ex. pour comparer deux échantillons
• G02B 21/02 - Objectifs
• G02B 21/24 - Structure du bâti ou statif
• G02B 21/26 - PlatinesMoyens de réglage pour celles-ci

Abrégé

This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

OF THE INVENTION USE OF VDAC AND LAMP1 AS MARKERS FOR DETECTING POCKED RED BLOOD CELLS Counting vacuole-containing RBC (pocked-RBC) is a robust marker of defective spleen function but requires the expertise of fewer and fewer specialized laboratory technicians. Now the inventors have identified VDAC and LAMP1 as markers for detecting pocked red blood cells. In particular, after performing a proteomic analysis, the inventors confirmed the presence of these proteins in splenectomized subjects by western blot. RBC of splectomized and control subjects were then marked with antibodies LAMP1 or VDAC and passed to cytometry. RBC from control subjects did not have labelling but there were RBC marked for splenectomized subjects. RBC labelling were then observed in DIC and pocked cells with vacuoles marked were quantified. No marked vacuole was observed in control subjects whereas between 4 and 33% of pocked cells had at least one vacuole marked with antibodies LAMP1 or VDAC. Since, these proteins are not found in control subjects, it is therefore possible to use this markers for detecting pocked RBCs and thus splenectomized subjects.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• G01N 33/80 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir les groupes ou les types sanguins

Abrégé

The invention relates to the use of a SQSTM1/p62 protein for modulating and predicting the response to: —an immunotherapy against immune checkpoint inhibitors: or—a combination of an immunotherapy, preferably an ICI, and a chemotherapy

Classes IPC  ?

• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur

Abrégé

The two nucleoredoxin genes, NXNL1 and NXNL2 encode by alternative splicing for a secreted truncated thioredoxin that mediates neuronal survival and a thioredoxin enzyme that regulates the phosphorylation of TAU. Behavioral analyses of young Nxnl2−/− mice demonstrate that this gene is involved in regulating of brain functions and is essential for learning and memory exerting positive effects on long-term potentiation (LTP) in the hippocampus. LTP dysfunction on the young Nxnl2−/− mice can be fully corrected by the synergistic action of the two products of the Nxnl2 gene. Aging Nxnl2−/− mice have brain stigmata of tauopathy as seen by oligomerization, phosphorylation and aggregation of TAU. This late occurring tauopathy can be prevented, by recombinant AAVs encoding RdCVF2 and RdCVF2L when administrated to young animals, which is of significant interest for therapeutic perspectives. Therefore, the present invention relates to a method of treating a tauopathy in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a first polynucleotide encoding for the short isoform of the NXNL2 gene. Rod-derived Cone Viability Factor (RdCVF2) and of a second polynucleotide encoding the long isoform of the NXNL2 gene, RdCVF2L.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
• C12N 15/86 - Vecteurs viraux

Abrégé

The disclosure relates to an automated system for processing physiological parameter measurements for providing a medical risk assessment, wherein it comprises: a module for receiving physiological parameter measurements (p1 . . . p15) for a female to be assessed; and a module for calculating a nonclassical 21-hydroxylase deficiency score (SNC21OHD) for the female to be assessed, according to a model which gives the score (SNC21OHD) on the basis of the measurements (p1 . . . p15) received. The physiological parameters comprise at least the following steroids: 21-deoxycortisol; 21-deoxycorticosterone; 11β-hydroxyandrostenedione; 17-OH-progesterone; androstenedione; corticosterone; and testosterone.

Classes IPC  ?

• G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
• G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
• G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
• G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients

Abrégé

A device for receiving radio frequency signals for a magnetic resonance imaging/spectroscopy system including an intracardiac receiving resonant loop and a switch capable of being alternately in an open state such that the frequency of the receiving antenna is tuned to an operating frequency of the magnetic resonance imaging system, and in a closed state such that the frequency of the receiving resonant loop is detuned, the receiving device including a first transmission line having a conductor with a distal end electrically connected to the receiving resonant loop and a proximal end electrically connected to the switch such that the switch is intended to be located outside the human body when the receiving resonant loop is located inside a patient's heart.

Classes IPC  ?

• G01R 33/36 - Détails électriques, p. ex. adaptations ou couplage de la bobine au récepteur
• G01R 33/28 - Détails des appareils prévus dans les groupes
• G01R 33/34 - Détails de structure, p. ex. résonateurs

Abrégé

Ultrasound-based wireless battery-free implantable sensors comprising a solution-gated field-effect transistor This disclosure relates to wireless battery-free implantable sensors for biomedical applications. Ultrasound-based wireless communication is proposed as an alternative to electromagnetic communication. The implantable sensor comprises a piezoelectric element and a variable impedance load whose value is a function of a physiological parameter of interest. The load is a solution-gated field-effect transistor (SG-FET), preferably a transistor with a graphene channel. The load is connected to the piezo-electric element for wireless communication with an external device. Experiments show that an ultrasound echo signal can be modulated by the gate voltage of the transistor and that the modulated signal can be transmitted through a propagation medium such a biological tissue.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus

Abrégé

in vitroin vivoin vivo. Thus, the present invention relates to an FMO inhibitor for use in the treatment of cancer in a subject in need thereof.

Classes IPC  ?

• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61K 31/495 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec deux azote comme seuls hétéro-atomes d'un cycle, p. ex. pipérazine
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux

Abrégé

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
• G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer